Guided Therapeutics, Inc. Announces Warrant Exchange and Issuance of Common Stock

Guided Therapeutics, Inc. (OTC: GTHP) has filed an 8-K report detailing a significant development regarding the company’s capital structure. The company, headquartered in Peachtree Corners, Georgia, completed a warrant exchange program that may have material implications for shareholders and potential investors.

Key Highlights of the Report

• Warrant Exchange Program Completed: On March 2, 2026, Guided Therapeutics, Inc. completed the exchange of certain outstanding warrants for shares of its common stock.
• Eligible Warrants: The exchange was available to holders of warrants issued in connection with the company’s Private Offering dated September 1, 2022.
• Exchange Ratio: Each eligible warrant was exchangeable for one share of common stock.
• Participation Rate: As of the expiration date (February 25, 2026), a total of 4,825,000 eligible warrant shares (representing approximately 22.7% of outstanding eligible warrants) were validly tendered and not withdrawn. All these were accepted by the company for exchange.
• Cash Proceeds: The company received aggregate cash proceeds of \$980,000 from the exercise of warrants in connection with the warrant exchange.
• Issuance of Common Stock: On March 2, 2026, the company issued 4,825,000 shares of restricted common stock, and all exchanged eligible warrants were cancelled.
• Pricing Incentive: Holders of eligible warrants originally priced at \$0.65 per share could exercise at \$0.25 per share, and those at \$0.50 per share could exercise at \$0.20 per share, provided all of a holder’s warrants of a given class were exercised by the deadline. For participants, the expiration of remaining unexercised warrants was extended by one year.
• Outstanding Warrants After Exchange: After completion, 16,398,080 eligible warrants remain outstanding (11,973,080 expiring between September 1 and October 18, 2026; 4,425,000 expiring between September 1 and October 18, 2027).
• Increase in Outstanding Shares: As a result of the exchange, the number of issued and outstanding shares of common stock increased from 86,691,976 to 91,516,976 as of March 2, 2026.
• Exemption from Registration: The shares were issued under Section 3(a)(9) of the Securities Act of 1933 as an exchange with existing security holders, with no commissions or compensation paid for solicitation.

Shareholder & Investor Considerations

• Dilution: The issuance of 4,825,000 new shares represents a dilution of approximately 5.6% relative to prior outstanding common shares. This may affect existing shareholders’ voting power and per-share earnings.
• Cash Infusion: The company received \$980,000 in cash, potentially strengthening its near-term liquidity and operational flexibility.
• Price-Sensitivity: The discounted exercise pricing of warrants relative to their original strike price, and the significant increase in issued shares, could impact the share price as the market digests the dilution and possible future conversions of the still-outstanding warrants.
• Extension of Warrant Expirations: Warrant holders who participated received a one-year extension on unexercised eligible warrants, which could delay further dilution but also incentivize future conversions if the stock price appreciates.
• No Commission Paid: No fees or commissions were paid for soliciting the exchange, minimizing outflow and maximizing proceeds to the company.

Potential Impact on Share Price

This transaction represents a material event for Guided Therapeutics, Inc. The combination of a substantial increase in outstanding common shares and a new influx of cash could:

• Lead to short-term price pressure due to dilution.
• Potentially improve the company’s financial flexibility and reduce overhang from outstanding warrants, should more be exercised in the future.
• Change the company’s capital structure, which may be relevant for both current and prospective investors evaluating the company’s financial health and future capital needs.

Leadership & Filing Information

• CEO: Mark L. Faupel signed the 8-K filing.
• Filing Date: March 9, 2026 (event date: March 2, 2026)
• Company Address: 5835 Peachtree Corners East, Suite B, Peachtree Corners, GA 30092

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The information is based on the company’s public filings and is believed to be accurate as of the date of publication. No representation or warranty is made regarding the completeness or accuracy of the information contained herein.

View GUIDED THERAPEUTICS INC Historical chart here